NJ State Employees Deferred Compensation Plan held its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 100,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. NJ State Employees Deferred Compensation Plan’s holdings in Celldex Therapeutics were worth $247,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of CLDX. Raymond James Financial Services Advisors Inc. increased its position in Celldex Therapeutics by 26.2% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,885 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 6,000 shares in the last quarter. Hikari Power Ltd bought a new position in Celldex Therapeutics during the first quarter worth $181,000. Creative Planning increased its position in Celldex Therapeutics by 12.2% in the second quarter. Creative Planning now owns 80,136 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 8,716 shares in the last quarter. American International Group Inc. increased its position in Celldex Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 58,838 shares of the biopharmaceutical company’s stock worth $212,000 after buying an additional 3,880 shares in the last quarter. Finally, Parametric Portfolio Associates LLC increased its position in Celldex Therapeutics by 2.2% in the first quarter. Parametric Portfolio Associates LLC now owns 65,884 shares of the biopharmaceutical company’s stock worth $238,000 after buying an additional 1,409 shares in the last quarter. 65.83% of the stock is currently owned by institutional investors.

Celldex Therapeutics, Inc. (NASDAQ CLDX) opened at 2.53 on Thursday. Celldex Therapeutics, Inc. has a 52 week low of $2.20 and a 52 week high of $5.02. The stock’s market cap is $316.51 million. The stock has a 50 day moving average of $2.47 and a 200-day moving average of $3.02.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.05. The firm had revenue of $3.83 million during the quarter, compared to analysts’ expectations of $1.21 million. Celldex Therapeutics had a negative net margin of 1,318.94% and a negative return on equity of 51.24%. The company’s revenue was up 175.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.32) earnings per share. Analysts forecast that Celldex Therapeutics, Inc. will post ($1.10) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/08/10/nj-state-employees-deferred-compensation-plan-maintains-stake-in-celldex-therapeutics-inc-cldx.html.

CLDX has been the topic of a number of recent analyst reports. HC Wainwright set a $10.00 price target on shares of Celldex Therapeutics and gave the stock a “buy” rating in a research note on Wednesday. Zacks Investment Research raised shares of Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research note on Tuesday, July 11th. Aegis reaffirmed a “buy” rating on shares of Celldex Therapeutics in a research note on Thursday, June 29th. Cowen and Company reaffirmed a “buy” rating on shares of Celldex Therapeutics in a research note on Tuesday, June 6th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and set a $3.50 price target (down previously from $4.00) on shares of Celldex Therapeutics in a research note on Thursday, May 11th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $7.32.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.